Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is st...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier
2016
|
| Online Access: | http://hdl.handle.net/1721.1/104801 https://orcid.org/0000-0001-5785-8911 |
| _version_ | 1826207783628832768 |
|---|---|
| author | DuPage, Michel J. Jacks, Tyler E. |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology DuPage, Michel J. Jacks, Tyler E. |
| author_sort | DuPage, Michel J. |
| collection | MIT |
| description | Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is strongly influenced by the surrounding microenvironment. Cells of the immune system are critical components of this extrinsic network of cancer regulators, contributing significantly to the microenvironment of most cancers and either promoting or inhibiting the initiation and progression of this disease. Genetically engineered mouse (GEM) mouse models of spontaneous cancer are starting to shape our understanding of how antitumor T cells may act to prevent or inhibit cancer progression in some settings and not others. Lessons learned from investigating spontaneous mouse cancer models have important implications for directing clinical efforts that attempt to direct a cancer patient's immune system to eradicate their disease. |
| first_indexed | 2024-09-23T13:54:53Z |
| format | Article |
| id | mit-1721.1/104801 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T13:54:53Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | mit-1721.1/1048012022-09-28T17:03:29Z Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response DuPage, Michel J. Jacks, Tyler E. Massachusetts Institute of Technology. Department of Biology Koch Institute for Integrative Cancer Research at MIT Jacks, Tyler E. DuPage, Michel J. Jacks, Tyler E. Cancer is a complex disease that can originate in virtually all the tissues of the body, and tumors progress through many different stages during their development. While genetic mutations in the emerging cancer cells drive this disease, it has become increasingly clear that cancer development is strongly influenced by the surrounding microenvironment. Cells of the immune system are critical components of this extrinsic network of cancer regulators, contributing significantly to the microenvironment of most cancers and either promoting or inhibiting the initiation and progression of this disease. Genetically engineered mouse (GEM) mouse models of spontaneous cancer are starting to shape our understanding of how antitumor T cells may act to prevent or inhibit cancer progression in some settings and not others. Lessons learned from investigating spontaneous mouse cancer models have important implications for directing clinical efforts that attempt to direct a cancer patient's immune system to eradicate their disease. National Institutes of Health (U.S.) (Grant 1 U54 CA126515-01) National Cancer Institute (U.S.) (Cancer Center Support (core) Grant P30-CA14051) John D. Proctor Foundation (Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award) Howard Hughes Medical Institute (Investigator) Virginia and Daniel K. Ludwig Graduate Fellowship 2016-10-13T19:02:20Z 2016-10-13T19:02:20Z 2013-04 Article http://purl.org/eprint/type/JournalArticle 09527915 http://hdl.handle.net/1721.1/104801 DuPage, Michel, and Tyler Jacks. “Genetically Engineered Mouse Models of Cancer Reveal New Insights About the Antitumor Immune Response.” Current Opinion in Immunology 25, 2 (April 2013): 192–199 https://orcid.org/0000-0001-5785-8911 en_US http://dx.doi.org/10.1016/j.coi.2013.02.005 Current Opinion in Immunology Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier PMC |
| spellingShingle | DuPage, Michel J. Jacks, Tyler E. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title | Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title_full | Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title_fullStr | Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title_full_unstemmed | Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title_short | Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| title_sort | genetically engineered mouse models of cancer reveal new insights about the antitumor immune response |
| url | http://hdl.handle.net/1721.1/104801 https://orcid.org/0000-0001-5785-8911 |
| work_keys_str_mv | AT dupagemichelj geneticallyengineeredmousemodelsofcancerrevealnewinsightsabouttheantitumorimmuneresponse AT jackstylere geneticallyengineeredmousemodelsofcancerrevealnewinsightsabouttheantitumorimmuneresponse |